About Us

It has exclusively licensed a clinically validated virus-like particle (VLP) platform from Cytos Biotechnology Ltd (SIX:CYTN) for the field of oncology, that includes the clinical product (CYT003) and technologies related to oligonucleotide synthesis and VLP delivery. CYT003 is a product derived from the CpG class of oligonucleotides that activates the immune system via Toll-like receptor 9 (TLR9) and has the potential to improve efficacy outcomes and broaden the size of the populations that can benefit from checkpoint inhibitor therapies.


Business size

1-10 employees


Commercial presence